Bayer requests VERQUVO be reimbursed for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure. Initiation criteria: In adult patients with New York Heart Association (NYHA) II to IV chronic HF Other HF therapies include an angiotensin-converting enzyme inhibitor (ACEi), an angiotensin II receptor antagonist (ARB) or an angiotensin receptor and neprilysin inhibitor (ARNi), a beta-blocker, and if tolerated, a mineralocorticoid receptor antagonist (MRA) VERQUVO should be initiated under the supervision of a healthcare professional who is experienced in the management of HF.
VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure.
Reimburse with clinical criteria and/or conditions
The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Call for patient/clinician input open
Call for patient/clinician input closed
- Patient input submission received from HeartLife Foundation and Heart function clinic Vancouver General Hospital, St Paul's Hospital
Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
CADTH review report(s) and responses to comments provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period
Final recommendation issued to sponsor and drug plans
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)